Sayama

Running trials

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· Phase 3· Source

• Active, not recruiting

  Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

  NCT03778229· Phase 2· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· Phase 3· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

  NCT03521154· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

  NCT03164616· Phase 3· Source

• Active, not recruiting

  Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  NCT03043872· Phase 3· Source

• Active, not recruiting

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· Phase 3· Source

• Completed

  A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)

  NCT04808518· Source

• Completed

  Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

  NCT03995875· Source

• Completed

  Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

  NCT03519971· Phase 3· Source

• Completed

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· Phase 3· Source

• Completed

  Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

  NCT02094261· Phase 2· Source

• Completed

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· Phase 2· Source